EUVIMEDEUVIMED entdecken
Open Access

Using Tumor Marker Gene Variants to Improve the Diagnostic Accuracy of DUPAN-2 and Carbohydrate Antigen 19-9 for Pancreatic Cancer

Yohei Ando iD, Mohamad Dbouk iD, Takeichi Yoshida, Helena Saba iD, Elizabeth Abou Diwan iD, Kanako Yoshida, Ali Dbouk iD, Amanda L Blackford iD, Ming-Tseh Lin, Anne Marie Lennon iD, Richard A Burkhart, Jin He iD und 4 weitere

Journal of Clinical Oncology · 20.06.2024 · 42 (18) · 2196-2206

DOI: 10.1200/jco.23.01573 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 20.06.2024. Verfasst von Yohei Ando und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Fucosyltransferases, CA-19-9 Antigen, Biomarkers, Tumor. Die Arbeit wurde bisher 45-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Circulating carbohydrate antigen 19-9 (CA19-9) levels reflect FUT3 and FUT2 fucosyltransferase activity. Measuring the related glycan, DUPAN-2, can be useful in individuals unable to synthesize CA19-9. We hypothesized that similar to CA19-9, FUT functional groups determined by variants in FUT3 and FUT2 influence DUPAN-2 levels, and having tumor marker reference ranges for each functional group would improve diagnostic performance. MATERIALS AND METHODS Using a training/validation study design, FUT2/ FUT3 genotypes were determined in 938 individuals from Johns Hopkins Hospital: 607 Cancer of the Pancreas Screening (CAPS) study subjects with unremarkable pancreata and 331 with pancreatic ductal adenocarcinoma (PDAC). Serum DUPAN-2 and CA19-9 levels were measured by immunoassay. RESULTS In controls, three functional FUT groups were identified with significant differences in DUPAN-2 levels: FUT3-intact, FUT3-null/FUT2-intact, and FUT3-null/FUT2-null. DUPAN-2 training set diagnostic cutoffs for each FUT group yielded higher diagnostic sensitivity in the validation set for patients with stage I/II PDAC than uniform cutoffs (60.4% [95% CI, 50.2 to 70.0] v 39.8% [30.0 to 49.8]), at approximately 99% (96.7 to 99.6) specificity. Combining FUT/CA19-9 and FUT/DUPAN-2 tests yielded 78.4% (72.3 to 83.7) sensitivity for stage I/II PDAC, at 97.7% (95.3 to 99.1) specificity in the combined sets, with higher AUC (stage I/II: 0.960 v 0.935 for CA19-9 + DUPAN-2 without the FUT test; P < .001); for stage I PDAC, sensitivity was 62.0% (49.1 to 73.2; AUC, 0.919 v 0.883; P = .03). CA19-9 levels in FUT3-null/FUT2-null PDAC subjects were higher than in FUT3-null/FUT2-intact subjects (median/IQR; 24.9/57.4 v

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pancreatic NeoplasmsFucosyltransferasesCA-19-9 AntigenBiomarkers, TumorGalactoside 2-alpha-L-fucosyltransferaseCarcinoma, Pancreatic DuctalHumansMiddle AgedFemaleMaleAgedGenotypeSensitivity and SpecificityAntigens, Neoplasm

Substanzen

FucosyltransferasesCA-19-9 AntigenBiomarkers, TumorGalactoside 2-alpha-L-fucosyltransferase3-galactosyl-N-acetylglucosaminide 4-alpha-L-fucosyltransferaseDU-PAN-2 antigen, humanAntigens, Neoplasm

Autor:innen und Institutionen

  • Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD.
  • Department of Oncology, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD.
  • Department of Surgery, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD.
  • Department of Medicine, The Sol Goldman Pancreatic Cancer Research Center, Johns Hopkins Medical Institutions, Baltimore, MD.

ORCID-Profile: Yohei Ando, Mohamad Dbouk, Helena Saba, Elizabeth Abou Diwan, Ali Dbouk, Amanda L Blackford, Anne Marie Lennon, Jin He, James R Eshleman, Marcia Irene Canto, Michael Goggins

Förderung

  • NCI NIH HHS

Zitieren

APA

Ando, Y., Dbouk, M., Yoshida, T., Saba, H., Abou Diwan, E., Yoshida, K., Dbouk, A., Blackford, A. L., Lin, M. T., Lennon, A. M., Burkhart, R. A., He, J., Sokoll, L., Eshleman, J. R., Canto, M. I., & Goggins, M. (2024). Using Tumor Marker Gene Variants to Improve the Diagnostic Accuracy of DUPAN-2 and Carbohydrate Antigen 19-9 for Pancreatic Cancer. Journal of Clinical Oncology, 42(18), 2196-2206. https://doi.org/10.1200/jco.23.01573

Vancouver

Ando Y, Dbouk M, Yoshida T, Saba H, Abou Diwan E, Yoshida K, et al. Using Tumor Marker Gene Variants to Improve the Diagnostic Accuracy of DUPAN-2 and Carbohydrate Antigen 19-9 for Pancreatic Cancer. Journal of Clinical Oncology. 2024;42(18):2196-2206. doi:10.1200/jco.23.01573

BibTeX
@article{Ando2024,
  author = {Ando, Yohei and Dbouk, Mohamad and Yoshida, Takeichi and Saba, Helena and Abou Diwan, Elizabeth and Yoshida, Kanako and Dbouk, Ali and Blackford, Amanda L and Lin, Ming-Tseh and Lennon, Anne Marie and Burkhart, Richard A and He, Jin and Sokoll, Lori and Eshleman, James R and Canto, Marcia Irene and Goggins, Michael},
  title = {Using Tumor Marker Gene Variants to Improve the Diagnostic Accuracy of DUPAN-2 and Carbohydrate Antigen 19-9 for Pancreatic Cancer},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {18},
  pages = {2196--2206},
  doi = {10.1200/jco.23.01573}
}
Kostenlos starten →